Breaking News, Collaborations & Alliances

Marker Therapeutics Partners with CellReady

Marker announces leadership transition & provides update on operational strategy.

Marker Therapeutics, Inc., a clinical-stage company specializing in the development of next-generation T cell-based immunotherapies for the treatment of cancer, entered an agreement with CellReady, a newly formed contract development and manufacturing organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corp. and Marker co-founder and board member. Under the terms of the agreement, CellReady will purchase certain cell manufacturing assets from Marker for approximately $1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters